AdipoRon; A Novel Insulin Sensitizer in Various Complications and the Underlying Mechanisms: A Review

(E-pub Ahead of Print)

Author(s): Ishfaq Ahmad Bhat, Shaheen Wasil Kabeer, Mohammad Irshad Reza, Reyaz Hassan Mir*, Muhammad Ovais Dar.

Journal Name: Current Molecular Pharmacology

Become EABM
Become Reviewer

Abstract:

Background: AdipoRon is the first synthetic analog of endogenous adiponectin, an adipose tissue-derived hormone. AdipoRon possesses pharmacological properties similar to adiponectin and its ability to bind and activate the adipoR1 and adipoR2 receptors make it a suitable candidate for the treatment of a multitude of disorders.

Objective: In the present review, an attempt was made to compile and discuss the efficacy of adipoRon against various disorders

Results: AdipoRon is an interesting drug which acts not only in metabolic diseases but in other conditions apparently unrelated to energy metabolism. It is well- reported that adipoRon exhibit strong anti-obesity, anti-diabetic, anti-cancer, anti-depressant, anti-ischemic, anti-hypertrophic properties and also improves conditions like post-traumatic stress disorder, anxiety, and systemic sclerosis.

Conclusion: A lot is known about its effects in experimental systems, but the translation of this knowledge to the clinic requires studies which, for many of the potential target conditions, have yet to be carried out. The beneficial effects of AdipoRon in novel clinical conditions will suggest an underlying pathophysiological role of adiponectin and its receptors in previously unsuspected settings.

Keywords: Adiponectin, adipokines, adipoR agonist, AdipoRon, an insulin sensitizer, metabolic disorders, cancer, CNS disorders

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1874467212666191022102800
Price: $95

Special-new-year-discount